Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(45 sites)

China

The first affiliated hospital of bengbu medical college, Bengbu, Anhui

The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui

Beijing CHAO-YANG Hospital Capital Medcal University, Beijing, Beijing Municipality

Peking university People's Hospital, Beijing, Beijing Municipality

Xinqiao Hospital of Army Medical University, Chongqing, Chongqing Municipality